Published on
August 27, 2026
- 15:25 GMT
Acuamark Diagnostics Announces Two Peer-Reviewed Publications on Sequencing-Free Blood Test for Early Colorectal Cancer
Top models achieved 92% sensitivity at 97% specificity across Stages I–IV colorectal cancer in a validation subset — on a PCR-based assay NEW YORK, NY, UNITED STATES, August 27, 2026 /EINPresswire.com/ -- Acuamark Diagnostics, Inc. (“AcuamarkDx” or “ …
Distribution channels:
Banking, Finance & Investment Industry, Companies
...
